301230 Stock Overview
Operates as a CRO, CDMO, and CMO service provider of drug discovery in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
PharmaResources (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥18.79 |
| 52 Week High | CN¥42.30 |
| 52 Week Low | CN¥16.28 |
| Beta | 0 |
| 11 Month Change | -5.39% |
| 3 Month Change | -17.26% |
| 1 Year Change | -45.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.25% |
Recent News & Updates
PharmaResources (Shanghai) (SZSE:301230) Posted Weak Earnings But There Is More To Worry About
May 02
Shareholder Returns
| 301230 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -0.8% | 1.1% | 1.1% |
| 1Y | -46.0% | -41.8% | -20.4% |
Return vs Industry: 301230 underperformed the CN Life Sciences industry which returned -41.8% over the past year.
Return vs Market: 301230 underperformed the CN Market which returned -20.4% over the past year.
Price Volatility
| 301230 volatility | |
|---|---|
| 301230 Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.5% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 301230's share price has been volatile over the past 3 months.
Volatility Over Time: 301230's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,012 | Ping Chen | www.pharmaresources.cn |
PharmaResources (Shanghai) Co., Ltd. operates as a CRO, CDMO, and CMO service provider of drug discovery in China. It also manufactures APIs and key intermediates. The company offers preclinical services.
PharmaResources (Shanghai) Co., Ltd. Fundamentals Summary
| 301230 fundamental statistics | |
|---|---|
| Market cap | CN¥2.60b |
| Earnings (TTM) | CN¥20.71m |
| Revenue (TTM) | CN¥517.83m |
125.5x
P/E Ratio5.0x
P/S RatioIs 301230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301230 income statement (TTM) | |
|---|---|
| Revenue | CN¥517.83m |
| Cost of Revenue | CN¥399.31m |
| Gross Profit | CN¥118.52m |
| Other Expenses | CN¥97.81m |
| Earnings | CN¥20.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 22.89% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 1.9% |
How did 301230 perform over the long term?
See historical performance and comparison